Hepatitis C Virus (HCV) NS5B Drug Resistance Assay
Also known as: HCV Drug Resistance, NS5B Resistance Analysis
Use
Assessment of drug susceptibility by nucleic acid sequencing of a patient's hepatitis C virus (HCV) to the NS5B inhibitors. Assay should be used for patients with documented HCV genotype 1.
Special Instructions
Patients should indicate their HCV genotype (1a or 1b) on the test request form. A separate frozen specimen is required for each test ordered to avoid delays in processing.
Limitations
The success of this procedure may be compromised if the HCV viral load is less than 1000 IU/mL. The assay specifically requires an HCV genotype of either 1a or 1b to provide accurate results. Additionally, the procedure might not succeed if the specimen has undergone repeated freeze/thaw cycles or is submitted in improper tubes.
Methodology
NGS
Biomarkers
LOINC Codes
- 72862-6
- 73655-3
- 49549-9
Result Turnaround Time
10-14 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
2 mL
Minimum Volume
1 mL
Container
Ship in plasma preparation tube (PPT™) or screw-capped polypropylene frozen transport tubes.
Collection Instructions
Collect specimen in two PPT™ tubes or lavender-top (EDTA) tubes. Do not use green-top tubes. Centrifuge within six hours, transfer to polypropylene screw-capped tubes, and freeze.
Storage Instructions
Freeze.
Causes for Rejection
PPT™ not centrifuged; insufficient volume; heparinized plasma; nonfrozen specimens; specimens exposed to repeated freeze/thaw cycles; specimen received in 'pop-top' or 'snap-cap' tube